DXCM vs RMD: fair value comparison
DexCom, Inc. and ResMed Inc. · Updated 2026-09-06
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, DXCM currently sits closer to the top of our discount ranking. DXCM carries the stronger momentum grade.
| DXCM | RMD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $87.90 | $228.35 |
| 12-month range | $58.22–$90.14 | $186.44–$257.39 |
| Sector rank | #20 of 113 Healthcare | #24 of 113 Healthcare |
| Quality grade | A | A |
| Momentum grade | A | B |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Expanding |
| Revenue growth | Strong | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: DXCM fair value analysis · RMD fair value analysis